Short answer
Vir Biotechnology, Inc. (VIR) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). $150 million common-stock offering: 15 million shares at $10.00 each.
Vir Biotechnology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $150 million common-stock offering: 15 million shares at $10.00 each
- Expected net proceeds $140.4 million, increasing to $161.5 million with full option exercise
- Underwriters’ 30-day option for 2.25 million additional shares, creating potential further dilution
- Expected November 16, 2026 closing, subject to customary conditions
- Proceeds strengthen Vir’s cash resources, while new shares dilute existing shareholders
Item 8.01 · Other Events
- Proposed common stock offering announced on November 12, 2026, signaling potential equity financing and shareholder dilution
- Offering priced the same day, indicating the transaction advanced from proposal toward execution
- Investors should review Exhibits 99.1 and 99.2 for offering size, price, proceeds and closing terms
Item EX-99.1 · Exhibit EX-99.1
- Vir Biotechnology announced a proposed underwritten public offering of common stock, creating potential shareholder dilution
- Underwriters may purchase up to 15% additional shares through a 30-day option
- Offering size, price and terms remain unspecified, with completion dependent on market conditions
- Proceeds could support clinical-stage hepatitis delta and oncology programs, but use of proceeds was not stated
- Leerink Partners, Morgan Stanley and Evercore ISI are bookrunning managers
Item EX-99.2 · Exhibit EX-99.2
- Public offering priced at $10.00 per share for 15,000,000 shares, raising expected gross proceeds of $150 million
- Underwriter option for 2,250,000 additional shares, creating further potential dilution and capital
- Vir receives all offering proceeds, supporting funding for clinical-stage hepatitis delta and oncology programs
- Offering expected to close November 16, 2026, subject to customary conditions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vir Biotechnology, Inc. 8-K filings
Get the next VIR 8-K as it lands
Follow VIR for push alerts, or ask the research agent what this filing means.